BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 17178762)

  • 1. Successful treatment of refractory neuro-Behcet's disease with infliximab: a case report to show its efficacy by magnetic resonance imaging, transcranial magnetic stimulation and cytokine profile.
    Fujikawa K; Aratake K; Kawakami A; Aramaki T; Iwanaga N; Izumi Y; Arima K; Kamachi M; Tamai M; Huang M; Nakamura H; Nishiura Y; Origuchi T; Ida H; Eguchi K
    Ann Rheum Dis; 2007 Jan; 66(1):136-7. PubMed ID: 17178762
    [No Abstract]   [Full Text] [Related]  

  • 2. Infliximab for the treatment of Neuro-Behçet's disease: a case series and review of the literature.
    Pipitone N; Olivieri I; Padula A; D'angelo S; Nigro A; Zuccoli G; Boiardi L; Salvarani C
    Arthritis Rheum; 2008 Feb; 59(2):285-90. PubMed ID: 18240181
    [No Abstract]   [Full Text] [Related]  

  • 3. Successful treatment of genital ulcers with infliximab in Behcet's disease.
    Haugeberg G; Velken M; Johnsen V
    Ann Rheum Dis; 2004 Jun; 63(6):744-5. PubMed ID: 15140785
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of infliximab in progressive neuro-Behçet's syndrome.
    Kikuchi H; Aramaki K; Hirohata S
    J Neurol Sci; 2008 Sep; 272(1-2):99-105. PubMed ID: 18550081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of infliximab on refractory uveitis in Behcet's disease.
    Sayarlioglu M; Cinal A; Topcu N; Demirok A
    Ann Pharmacother; 2004 May; 38(5):901-2. PubMed ID: 15010522
    [No Abstract]   [Full Text] [Related]  

  • 6. Switching to adalimumab is effective in a case of neuro-Behcet's disease refractory to infliximab.
    Leccese P; D'Angelo S; Angela P; Coniglio G; Olivieri I
    Clin Exp Rheumatol; 2010; 28(4 Suppl 60):S102. PubMed ID: 20868587
    [No Abstract]   [Full Text] [Related]  

  • 7. [Treatment of severe Behçet's disease with anti-TNF-alpha: infliximab. A case report].
    Andreu M; Ramanoelina J; Fajnkuchen F; Mouthon L; Cohen P; Laroche L; Guillevin L
    Ann Med Interne (Paris); 2002 Oct; 153(6):414-5. PubMed ID: 12486393
    [No Abstract]   [Full Text] [Related]  

  • 8. Successful use of infliximab in a patient with neuro-Behçet's disease.
    Abalos-Medina GM; Sánchez-Cano D; Ruiz-Villaverde G; Ruiz-Villaverde R; Quirosa Flores S; Raya Alvarez E
    Int J Rheum Dis; 2009 Sep; 12(3):264-6. PubMed ID: 20374357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful treatment of long-standing neuro-Behçet's disease with infliximab.
    Sarwar H; McGrath H; Espinoza LR
    J Rheumatol; 2005 Jan; 32(1):181-3. PubMed ID: 15630746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful treatment of refractory Behçet's disease with the TNF-alpha blocker infliximab.
    Jalili A; Kinaciyan T; Barisani T; Peck-Radosavljevic M; Stingl G; Geusau A; Wöhrl S
    Iran J Immunol; 2009 Mar; 6(1):55-8. PubMed ID: 19293479
    [No Abstract]   [Full Text] [Related]  

  • 11. Blind insight: eyeing anti-tumor necrosis factor treatment in uveitis associated with Behçet's disease.
    Rosenbaum JT
    J Rheumatol; 2004 Jul; 31(7):1241-3. PubMed ID: 15229938
    [No Abstract]   [Full Text] [Related]  

  • 12. Anti-TNF therapy in the management of Behcet's disease--review and basis for recommendations.
    Sfikakis PP; Markomichelakis N; Alpsoy E; Assaad-Khalil S; Bodaghi B; Gul A; Ohno S; Pipitone N; Schirmer M; Stanford M; Wechsler B; Zouboulis C; Kaklamanis P; Yazici H
    Rheumatology (Oxford); 2007 May; 46(5):736-41. PubMed ID: 17403712
    [No Abstract]   [Full Text] [Related]  

  • 13. Interferon-a (IFN-a) application versus tumor necrosis factor-a antagonism for ocular Behçet's disease: focusing more on IFN.
    Kotter I; Deuter C; Stubiger N; Zierhut M
    J Rheumatol; 2005 Aug; 32(8):1633; author reply 1634. PubMed ID: 16078350
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of anti-TNF-alpha antibody infliximab in refractory entero-Behcet's disease.
    Iwata S; Saito K; Yamaoka K; Tsujimura S; Nawata M; Suzuki K; Tanaka Y
    Rheumatology (Oxford); 2009 Aug; 48(8):1012-3. PubMed ID: 19465589
    [No Abstract]   [Full Text] [Related]  

  • 15. Adalimumab: a new modality for Behçet's disease?
    van Laar JA; Missotten T; van Daele PL; Jamnitski A; Baarsma GS; van Hagen PM
    Ann Rheum Dis; 2007 Apr; 66(4):565-6. PubMed ID: 17124248
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis.
    Ohno S; Nakamura S; Hori S; Shimakawa M; Kawashima H; Mochizuki M; Sugita S; Ueno S; Yoshizaki K; Inaba G
    J Rheumatol; 2004 Jul; 31(7):1362-8. PubMed ID: 15229958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful treatment of severe Behçet's disease with infliximab in an Italian Olympic athlete.
    Olivieri I; Latanza L; Siringo S; Peruz G; Di Iorio V
    J Rheumatol; 2008 May; 35(5):930-2. PubMed ID: 18464316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A patient with neuro-Behçet's disease is successfully treated with etanercept: further evidence for the value of TNFalpha blockade.
    Alty JE; Monaghan TM; Bamford JM
    Clin Neurol Neurosurg; 2007 Apr; 109(3):279-81. PubMed ID: 17174468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Behçet's disease and the possibilities of modern tumour necrosis factor inhibiting medication].
    van Laar JA; Jamnitski A; Baarsma GS; van Daele PL; van Hagen PM
    Ned Tijdschr Geneeskd; 2006 Apr; 150(13):705-9. PubMed ID: 16623340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infliximab treatment for severe orogenital ulceration in Behçet's disease.
    Connolly M; Armstrong JS; Buckley DA
    Br J Dermatol; 2005 Nov; 153(5):1073-5. PubMed ID: 16225632
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.